

# Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

Horizon Europe

<b>CODICE</b>	<b>AMBITO</b>
HORIZON-MISS-2026-02-CANCER-03	Internazionale
<b>LOCALITÀ</b>	<b>STATO</b>
Europa	Aperto
<b>PROGRAMMA</b>	<b>CURATO DA</b>
Horizon Europe	Maria Macedo
<b>GENERATO IL</b>	
28 aprile 2026	

## Descrizione

### Objectives

This incentive is part of the Horizon Europe framework and is aligned with missions focusing on cancer research and related innovations. It aims to support eligible organizations across Europe, including research institutions, universities, public and private entities, and consortia that can deliver solutions advancing the fight against cancer. The incentive targets advancements in prevention, diagnosis, treatment, and patient care by fostering collaboration at the European level. Eligible companies are those that can demonstrate expertise and the capacity to contribute to impactful R&I in the oncology field and support the objectives outlined by Horizon Europe and the EU's Cancer Mission.

### Project Types

Supported project types typically include collaborative research and innovation actions, demonstration projects, clinical trials, technology validation, capacity building, and best-practice dissemination. Eligible expenses often cover direct research costs, personnel, equipment, consumables, dissemination, communication, coordination, networking, and potentially sub-contracting. Projects advancing technological solutions, new methodologies, or establishing EU-wide data infrastructures in cancer are encouraged. Eligible activities should align with the work programme's thematic focus and directly contribute to measurable EU mission objectives.

### Funding

The funding from Horizon Europe is generally provided as non-refundable grants. The maximum funding rate for eligible entities under Horizon Europe Research and Innovation Actions can reach up to 100% for non-profit entities and 70% for commercial entities, including indirect costs calculated at a flat rate. Budget limits and minimum or maximum project values are defined by the specific topic and work programme, with typical EU contribution guidelines

provided for each call. The total call budget and upper/lower project amounts will be provided in the Work Programme or topic description on the Funding & Tenders Portal. Applicants should carefully consult these documents to determine the eligibility of their cost structures and financial needs.

### Key Aspects

The maximum project duration, result indicators, and critical rules are specified in the Work Programme. Typically, durations range from 24 to 48 months. Key result indicators may include scientific output, clinical milestones, innovation uptake, and patient impact. Selection and eligibility rules are governed by Horizon Europe regulations, focusing on scientific excellence, impact, implementation quality, consortium capability, and EU value added. All proposals must comply with specific eligibility and ethics requirements detailed in the Work Programme.

---

## Date e Scadenze

### DATA DI PUBBLICAZIONE

Non definita

### DATA DI APERTURA

10 febbraio 2026

### Fasi di Candidatura

- Deadline: 15 settembre 2026 alle ore 16:00 (140 giorni rimanenti)

---

## Dettagli Finanziari

### TIPO DI SUPPORTO

Contributo a Fondo Perduto

### TASSO MASSIMO DI FINANZIAMENTO

100%

### BUDGET

22.2M€

### VALORE DI PROGETTO AMMISSIBILE

Up to 8M€

### DURATA MASSIMA

60 mesi

---

## Criteri e Documenti

### Spese Ammissibili

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

### Condizioni di Accesso

- Legal entities from EU Member States and Associated Countries
- Consortium must include partners from at least three different EU Member States or Associated Countries
- Compliance with general and specific admissibility and eligibility criteria

### Criteri di Selezione

- Excellence (scientific and technical merit)

- Impact (contribution to policy and partnership KPIs)
- Quality and efficiency of implementation

### Informazioni Obbligatorie

- Application form (Part A and Part B)
- Budget

---

## Dettagli Programma UE

ID BANDO

PROGETTI PREVISTI

HORIZON-MISS-2026-02-CANCER-03

3

---

## Idoneità

### Settori Idonei

- Salute e Life Sciences

### Dimensioni Aziendali

- Micro
- PMI
- Small Mid-Cap
- Mid-Cap
- Grande
- Enti privati non profit
- Enti pubblici

### Modalità di Candidatura

- Consorzio / Co-promozione

---

## Link Ufficiali

Regolamento Ufficiale:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2026-02-CANCER-03?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&isExactMatch=true&status=31094501,31094502&programmePart=43108557&frameworkProgramme=43108390&deadlineDate=1780182000000,1798675200000>

Pagina Grantavia: <https://grantavia.com/it/incentives/pragmatic-clinical-trials-to-optimize-immunotherapeutic-interventions-for-patients-with-refractory-cancers>

Prenota un incontro: <https://calendly.com/ines-carreira-fi-group/reuniao>